Yeytuo ® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protection Accelerated EC Decision Comes After U.S. FDA Approval in June FOSTER CITY, Calif. / Aug 26, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo ® (lenacapavir)—the company’s twice-yearly injectable HIV-1... Read More